ИНДЕКС МАССЫ ТЕЛА И КОМПЛАЕНТНОСТЬ У БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА КОМОРБИДНЫХ С САХАРНЫМ ДИАБЕТОМ
Article Sidebar
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Main Article Content
Аннотация:
оценить взаимосвязь индекса массы тела и комплаености у больных ИБС коморбидных с сахарным диабетом.
Article Details
Как цитировать:
Библиографические ссылки:
Marie-Eve Piché, André Tchernof and Jean-Pierre Després. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. // Circulation Research. 2020;126:1477–1500. // https://doi.org/10.1161/CIRCRESAHA.120.316101
González-Muniesa P, Mártinez-González MA, Hu FB, Després JP, Matsuzawa Y, Loos RJF, Moreno LA, Bray GA, Martinez JA. Obesity.Nat Rev Dis Primers. 2017; 3:17034. doi: 10.1038/nrdp.2017.34.
MacLean PS, Wing RR, Davidson T, Epstein L, Goodpaster B, Hall KD, Levin BE, Perri MG, Rolls BJ, Rosenbaum M, et al. NIH working group report: innovative research to improve maintenance of weight loss.Obesity (Silver Spring). 2015; 23:7–15. doi: 10.1002/oby.20967.
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324:71–86.
Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S. Clopidogrel in unstable angina to prevent recurrent ischemic events trial. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non–ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004; 110:1202–1208.
Hognestad A, Dickstein K, Myhre E, Snapinn S, Kjekshus J. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol. 2004; 93:603–606.
Newby LK, LaPointe NMA, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006; 113:203–212.
Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2018; 155:772–779.
Sokol MC, Mcguigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalize statin risk and healthcare cost. Med Care. 2005; 43:521–530.
Raghavan S, Vassy JL, Ho YL, et al.. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc 2019;8:e011295.
Chen Y, Copeland WK, Vedanthan R, et al.. Association between body mass index and cardiovascular disease mortality in East Asians and South Asians: pooled analysis of prospective data from the Asia Cohort Consortium. BMJ 2013;347:f5446.
Di Angelantonio E, Bhupathiraju ShN, Wormser D, et al..; Global BMI Mortality Collaboration . Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776–786.
International Diabetes Federation. idf diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015.
International Diabetes Federation. Diabetes and cardiovascular disease. Brussels: International Diabetes Federation; 2016. p. 1–144.
Einarson, T.R., Acs, A., Ludwig, C. et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol 17, 83 (2018). https://doi.org/10.1186/s12933-018-0728-6.
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.
Salinero-Fort MA, San Andrés-Rebollo FJ, Gómez-Campelo P, et al. Body mass index and all-cause mortality among type 2 diabetes mellitus patients: findings from the 5-year follow-up of the MADIABETES cohort. Eur J Intern Med. 2017;43:46–52. doi: 10.1016/j.ejim.2017.06.021.
Bae JP, Lage MJ, Mo D, et al. Obesity and glycemic control in patients with diabetes mellitus: analysis of physician electronic health records in the US from 2009–2011. J Diabetes Complications. 2016;30(12):212–220. doi: 10.1016/j.jdiacomp.2015.11.016.
Boye KS, Lage MJ, Thieu V, et al. Obesity and glycemic control among people with type 2 diabetes in the United States: a retrospective cohort study using insurance claims data. J Diabetes Complications. 2021;35(9):107975. doi: 10.1016/j.jdiacomp.2021.107975.
Gray N, Picone G, Sloan F, et al. The relationship between BMI and onset of diabetes mellitus and its complications. South Med J. 2015;108(1):29–36. doi: 10.14423/SMJ.0000000000000214.
Boye KS, Lage MJ, Terrell K. Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity. J Diabetes Complications. 2020;34(12):107730. doi: 10.1016/j.jdiacomp.2020.107730.
Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83. doi: 10.1186/s12933-018-0728-6.
Hauber AB, Mohamed AF, Johnson FR, et al. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416–424. doi: 10.1111/j.1464-5491.2009.02696.x.
Morillas C, Feliciano R, Catalina PF, et al. Patients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Prefer Adherence. 2015;9:1443–1458. doi: 10.2147/PPA.S88022.
Mohamed AF, Zhang J, Johnson FR, et al. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Diabetes Metab. 2013;39(5):397–403. doi: 10.1016/j.diabet.2013.06.001.
Matza LS, Yurgin N, Boye KS, et al. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Curr Med Res Opin. 2007;23(9):2051–2062. doi: 10.1185/030079907X219454.
Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger P-M. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetic Med. 2012;29(5):682–689. doi: 10.1111/j.1464-5491.2012.03605.x
American Diabetes Association (ADA). Obesity management for the treatment of type 2 diabetes. Standards of Medical Care in Diabetes – 2021. Diabetes Care. 2021;44(suppl1):S100–110. doi: 10.2337/dc21-S008.
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701. doi: 10.2337/dci18-0033.
Kristina S Boye, Shraddha Shinde, Tessa Kennedy-Martin, Susan Robinson and Vivian T Thieu. Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review. // Patient Prefer Adherence. 2022; 16: 23–39. Published online 2022 Jan 6. doi: 10.2147/PPA.S328583.